<SEC-DOCUMENT>0001564590-14-004103.txt : 20140922
<SEC-HEADER>0001564590-14-004103.hdr.sgml : 20140922
<ACCEPTANCE-DATETIME>20140922161523
ACCESSION NUMBER:		0001564590-14-004103
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20140922
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20140922
DATE AS OF CHANGE:		20140922

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			DYNAVAX TECHNOLOGIES CORP
		CENTRAL INDEX KEY:			0001029142
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				330728374
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-34207
		FILM NUMBER:		141114212

	BUSINESS ADDRESS:	
		STREET 1:		2929 SEVENTH STREET
		STREET 2:		SUITE 100
		CITY:			BERKELEY
		STATE:			CA
		ZIP:			94710
		BUSINESS PHONE:		5108485100

	MAIL ADDRESS:	
		STREET 1:		2929 SEVENTH STREET
		STREET 2:		SUITE 100
		CITY:			BERKELEY
		STATE:			CA
		ZIP:			94710
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>dvax-8k_20140922.htm
<DESCRIPTION>8-K
<TEXT>
<html>
<body>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="margin-top:0pt;text-align:center;border-top:Solid 1pt;padding-top:1pt;margin-bottom:0pt;line-height:1pt;border-top:Solid 0.75pt #000000;padding-top:0pt;text-indent:0%;font-size:4pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-top:0pt;text-align:center;border-top:Solid 1pt;padding-top:1pt;margin-bottom:0pt;line-height:1pt;border-top:Solid 0.75pt #000000;padding-top:0pt;text-indent:0%;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;<font style="font-size:12pt;"> </font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#;font-size:13.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">UNITED STATES </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#;font-size:13.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SECURITIES AND EXCHANGE COMMISSION<font style="font-weight:normal;"> </font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Washington, D.C. 20549<font style="font-weight:normal;"> </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;<font style="font-size:12pt;"> </font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Form 8-K </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;<font style="font-size:12pt;"> </font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#;font-size:13.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CURRENT REPORT<font style="font-weight:normal;"> </font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#;font-size:13.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934<font style="font-weight:normal;"> </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;<font style="font-size:12pt;"> </font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Date of Report (Date of earliest event reported):&#160;&#160;09/22/2014 </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;<font style="font-size:12pt;"> </font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Dynavax Technologies Corporation<font style="font-weight:normal;"> </font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Exact name of registrant as specified in its charter)<font style="font-weight:normal;"> </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;<font style="font-size:12pt;"> </font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Commission File Number:&#160;&#160;001-34207<font style="font-weight:normal;"> </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;<font style="font-size:12pt;"> </font></p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:59%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Delaware<font style="font-weight:normal;"> </font></p></td>
<td valign="bottom"  style="width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; </p></td>
<td valign="bottom"  style="width:59%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">33-0728374<font style="font-weight:normal;"> </font></p></td>
</tr>
<tr>
<td valign="top"  style="width:59%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:-12.25pt;;font-weight:bold;color:#;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(State or other jurisdiction of<font style="font-weight:normal;"> </font></p></td>
<td valign="bottom"  style="width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; </p></td>
<td valign="bottom"  style="width:59%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(IRS Employer<font style="font-weight:normal;"> </font></p></td>
</tr>
<tr>
<td valign="top"  style="width:59%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:-12.25pt;;font-weight:bold;color:#;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">incorporation)<font style="font-weight:normal;"> </font></p></td>
<td valign="bottom"  style="width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; </p></td>
<td valign="bottom"  style="width:59%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Identification No.)<font style="font-weight:normal;"> </font></p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;<font style="font-size:12pt;"> </font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2929 Seventh Street, Suite 100</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Berkeley, CA 94710-2753<font style="font-weight:normal;"> </font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Address of principal executive offices, including zip code)<font style="font-weight:normal;"> </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;<font style="font-size:12pt;"> </font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(510) 848-5100<font style="font-weight:normal;"> </font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Registrant&#8217;s telephone number, including area code)<font style="font-weight:normal;"> </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;<font style="font-size:12pt;"> </font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Former name or former address, if changed since last report)<font style="font-weight:normal;"> </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;<font style="font-size:12pt;"> </font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">[&#160;&#160;]&#160;&#160; Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)<br><br>[&#160;&#160;]&#160;&#160; Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)<br><br>[&#160;&#160;]&#160;&#160; Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))<br><br>[&#160;&#160;]&#160;&#160; Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;<font style="font-size:12pt;"> </font></p>
<p style="margin-top:0pt;text-align:center;border-top:Solid 1pt;padding-top:1pt;margin-bottom:0pt;line-height:1pt;border-top:Solid 0.75pt #000000;padding-top:0pt;text-indent:0%;font-size:4pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-top:0pt;text-align:center;border-top:Solid 1pt;padding-top:1pt;margin-bottom:0pt;line-height:1pt;border-top:Solid 0.75pt #000000;padding-top:0pt;text-indent:0%;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;<font style="font-size:12pt;"> </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Item 8.01.&#160;&#160;&#160;&#160;Other Events</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;<font style="font-size:12pt;"> </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.94%;color:#;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On September 22, 2014, we issued a press release titled "Dynavax Completes Enrollment of Phase 3 Study of HEPLISAV-B&#8482;." A copy of the press release is attached as Exhibit 99.1 to this current report and is incorporated herein by reference. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;<font style="font-size:12pt;"> </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;<font style="font-size:12pt;"> </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Item 9.01.&#160;&#160;&#160;&#160;Financial Statements and Exhibits<font style="font-weight:normal;"> </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;<font style="font-size:12pt;"> </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;color:#;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d) Exhibits. The following exhibit is furnished herewith: </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">99.1 Press Release, dated September 22, 2014, titled "Dynavax Completes Enrollment of Phase 3 Study of HEPLISAV-B&#8482;" </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;<font style="font-size:12pt;"> </font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SIGNATURES<font style="font-weight:normal;"> </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;<font style="font-size:12pt;"> </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;color:#;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;<font style="font-size:12pt;"> </font></p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:99.75%;">
<tr>
<td style="width:7.37%;"></td>
<td style="width:44.98%;"></td>
<td style="width:6.81%;"></td>
<td style="width:40.6%;"></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dynavax Technologies Corporation</p></td>
</tr>
<tr style="height:24pt;">
<td valign="bottom"  style=" border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date:</p></td>
<td valign="bottom"  style=" border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">September 22, 2014</p></td>
<td valign="bottom"  style=" border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="bottom"  style=" border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#8195;<font style="color:#;"> David Johnson</font></p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">David Johnson</p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vice President</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">EXHIBIT INDEX<font style="font-weight:normal;"> </font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100.22%;">
<tr style="height:30pt;">
<td valign="top"  style="width:10.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit No.<font style="font-weight:normal;"> </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p></td>
<td valign="top"  style="width:2.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:87.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Description<font style="font-size:12pt;font-weight:normal;color:#000000;"> </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p></td>
</tr>
<tr style="height:25.6pt;">
<td valign="top"  style="width:10.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EX-99.1 </p></td>
<td valign="top"  style="width:2.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:87.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Press Release, dated September 22, 2014, titled "Dynavax Completes Enrollment of Phase 3 Study of HEPLISAV-B&#8482;"</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>dvax-ex991_201409226.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html>
<body>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 99.1</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#0000FF;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g201409221651321481234.jpg" style="width:160.5pt;height:47.25pt"><font style="font-family:Times New Roman;font-size:1pt;color:#FFFFFF;"></font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#145590;font-size:10pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">2929 Seventh Street, Suite 100</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#145590;font-size:10pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Berkeley, CA 94710</p>
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:65.36%;text-indent:-8.17%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:101.15%;">
<tr>
<td style="width:51.99%;"></td>
<td style="width:2.68%;"></td>
<td style="width:46.48%;"></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:1.13%;text-indent:0pt;;font-weight:bold;font-size:11pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Contact:</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:4.99%;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Michael S. Ostrach</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:4.99%;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr style="height:7.2pt;">
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vice President, Chief Business and Principal Financial Officer </p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr style="height:7.2pt;">
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">510-665-7257</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr style="height:7.2pt;">
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">mostrach@dynavax.com</font></p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Arial Bold;text-transform:uppercase;font-style:normal;font-variant: normal;"><a name="OLE_LINK9"></a>DYNAVAX COMPLETES ENROLLMENT OF PHASE 3 STUDY of HEPLISAV-B&#8482;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BERKELEY, CA &#8211; September 22, 2014 &#8211; Dynavax Technologies Corporation (NASDAQ: DVAX) today announced completion of planned enrollment in the ongoing phase 3 clinical trial of HEPLISAV-B, its investigational adult hepatitis B vaccine.&nbsp;&nbsp;More than 8,250 adults, including over 1,100 diabetic subjects, have been enrolled at 40 sites in the U.S.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This large safety and immunogenicity study (known as HBV-23) is intended to provide an adequately-sized database of vaccinated subjects to enable the U.S. Food and Drug Administration to complete its review of the pending HEPLISAV-B Biologics License Application.&nbsp;&nbsp;The study is also designed to assess the immunogenicity of HEPLISAV-B in adults for whom approved hepatitis B vaccines are less effective, including those with type-2 diabetes mellitus.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;Concluding enrollment of HBV-23 is a major milestone in the path to potential approval of HEPLISAV-B. I am pleased with the team&#8217;s efforts to complete this key phase of the trial three months ahead of schedule&#8221; said Eddie Gray, Chief Executive Officer of Dynavax. &#8220;HEPLISAV-B is the most advanced demonstration of our leadership in TLR biology and validates our targeted approach to modulating the immune system to prevent and treat disease.&#8221;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HBV-23 is an observer-blinded, randomized, active-controlled trial.&nbsp;&nbsp;Adult subjects between the ages of 18 and 70 have been randomized in a 2:1 ratio to receive a 2-dose series of HEPLISAV-B or a 3-dose series of the control vaccine, Engerix-B<sup style="font-size:85%; vertical-align:top">&#174;</sup>.&nbsp;&nbsp;Safety follow up will continue for 12 months following each subject&#8217;s second vaccination.&nbsp;&nbsp;All study visits will be completed by October, 2015.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additional details regarding HBV-23 are available at <font style="text-decoration:underline;">www.clinicaltrials.gov</font>.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">About HEPLISAV-B</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HEPLISAV-B is an investigational adult hepatitis B vaccine that combines hepatitis B surface antigen with a proprietary Toll-like Receptor 9 agonist to enhance the immune response. Dynavax has worldwide commercial rights to HEPLISAV-B.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">About Dynavax</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dynavax, a clinical-stage biopharmaceutical company, discovers and develops novel vaccines and therapeutics in the areas of infectious and inflammatory diseases and oncology. Dynavax's lead product candidate is HEPLISAV-B, a Phase 3 investigational adult hepatitis B vaccine. For more information visit <font style="text-decoration:underline;">www.dynavax.com</font>.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#;font-size:11pt;font-family:Arial;font-style:italic;text-transform:none;font-variant: normal;">Forward-Looking Statements</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This press release contains "forward-looking" statements, including expectations for the conduct, timing and sufficiency of HBV-23. Actual results may differ materially from those set forth in this press release due to the risks and uncertainties inherent in our business, including whether a sufficient number of subjects enrolled in HBV-23 complete the study; whether successful clinical and regulatory development and review and approval of HEPLISAV-B and our process for its manufacture can occur without significant delay or additional studies; whether our studies and manufacturing efforts are sufficient to support registration for commercialization of HEPLISAV-B; our ability to obtain additional financing to support the development and commercialization of HEPLISAV-B and our other operations; possible claims against us, including enjoining sales of HEPLISAV-B, based on the patent rights of others; and other risks detailed in the "Risk Factors" section of our current periodic reports with the&#160;SEC. We undertake no obligation to revise or update information herein to reflect events or circumstances in the future, even if new information becomes available. Information on&#160;Dynavax's&#160;website at&#160;<font style="text-decoration:underline;color:#000000;">www.dynavax.com</font>&#160;is not incorporated by reference in our current periodic reports with the&#160;SEC.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"># # #</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:12pt;line-height:10pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:8.17%;"><font style="margin-left:36pt;"></font></p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g201409221651321481234.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g201409221651321481234.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``@&!@<&!0@'!P<)"0@*#!0-#`L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+#`Q-#0T'R<Y/3@R/"XS-#+_
MVP!#`0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P``1"`$9`Z<#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#W^BBB@`HH
MHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB
M@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`
M"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`*
M***`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HH
MHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB
M@`HHHH`****`"BBB@`HHHH`**9+-%"`994C!Z%V`S6?+XAT:#[^IVO7&%E#'
M]*`-.BL%_&?A]&*G41D>D3D?F%JM_P`)]H?_`#TG_P"_1H"YT]%<G)\0]&1L
M+%>2#^\L:X_5A3/^%C:1_P`^U]_WPG_Q5`7.OHKD/^%C:1_S[7W_`'PG_P`5
M4D7Q"T:0D,EW'CNT8Y_(F@+G5T5S<?CO07;#7$D8QU:)L?IFKL'BC0[C&S4X
M!G_GH=G_`*%B@#7HIJ2)*@>-U=3T93D&G4`%%%%`!1110`4444`%%%%`!111
M0`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`
M!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%
M%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`44
M44`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!111
M0`4444`%%%%`'G_B'QOJ-EJES8VD4$:Q-M\Q@68_T_2N6N?$>LW>?-U*XP<Y
M"/L!S[+@5U6J^!]1U37+N[$UO%!+(2NYB6QCT`_K3(?AK*2?.U-%';9$6S^9
M&*9.IPKNTC%G8LQZDG)-)79Z]X%&F:9+>VUXTHB`+QNH!(SU!_I7&4P"BBB@
M04^*&68D11/(1U"J3BO0/`&EV%SI4UU<6D,LZW!17D4-@!5(QGIR>M=RB+&@
M5%"J.@`P!2N.QX7]AO/^?6?_`+]FHY8)H,>;$\>>F]2,U[S2,H=2K`%2,$$<
M$47'8\#HKV:^\,:-J`/G6,2N>=\0V-^G7\:X_5_A[<0`RZ7-]H0?\LI"`_X'
MH?THN*QQ]M>7-G)YEM<2POZQN5/Z5T^F?$#4K3"7J)>1CN?D?\QQ^8_&N4DB
MDAE:.5&213AE88(/H13:8'LVC^)--UL;;:7;/C)ADX8?X_A6O7@:.T;JZ,59
M3D,#@@^M=[X9\<G*6>L2<=$N3_)O\?S]:5AIG?T4`@@$'(/0BBD,****`"BB
MB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****
M`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`
M****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`H
MHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BB
MB@`HHHH`****`"BBB@`HHHH`R/%/_(KZA_UR/\Z\9KV;Q3_R*^H?]<C_`#KQ
MFFB6%%%%,1Z=\.?^1>N/^OIO_0$KKZY#X<_\B]<?]?3?^@)77U):"BBB@`HH
MHH`P_$7AFUUVW+86*\4?NYL?HWJ/Y5Y+>6=QI]W):W49CFC.&4_S^E>[5ROC
M7P^NI:<U[`G^EVRD\=73N/?'4?CZTT)H\LHHHIDG:^#?%C6LD>F7\G^C-Q%*
MQ_U9]"?3^7TZ>D5X%7J/@CQ`VIV365R^ZZMQP3U=.F3[@\?E2929UE%%%(84
M5YGK_B[6K37;RWMKORH8I"BKY2'@?4&L]/&_B!6!-\&`_A,*8/Y"G85SURBO
M*D\?ZXA4LUNX'4-%U_(BK*?$;5`X,EK9LO<*K`_GN-%@N>F45YS_`,+)O/\`
MH'P?]]FD;XD7I4[;"W#8X)9B,T6"YZ/17GVC>-]3U+7+.UFCMDBD?:PC0@G(
M]237H-(84444`%%<9XT\0:EHU_:+93A$>,LRE%8,<^XS7.?\)]KG_/2#_OT*
M=A7/5J*\S3XC:H'!DM;-E[A58'\]QHD^(^J%OW=I9JOHP8G\]PHL%STRBN2\
M)>)K[7KRYCND@18HPP$2D<Y]R:ZVD,**\OO/'&N6][/#NA7RY&3!BY&#BH3X
M]UT@CS81[^4*=A7/5J*\H3QYKJJ`9H6(_B,0R?RI)/'>O.N%N(HS_>6)<_KF
MBP7/6**\IL_'>M07<<ES.+B$'YXC&BY'U`R#7I6FZG::M:+<V<H=#P1W4^A'
M8T@N7****!A1110`4444`%%>5O\`$#6W<LIMD!_A6/@?F33'\>:ZRD":%2?X
MA$,C\Z=A7/5Z*\A_X37Q#_T$/_(,?_Q-12>+=>E?<VI2@_[(51^0%%@N>QT5
MY#9>)=<FO[>,ZA.X:105]1FO7J07"BBB@84444`%%%%`!17B_B34O[5UZZN5
M;,>[9'Z;1P,?7K^-+X:U0Z3KMO<%ML3'RY?38>N?IP?PIV%<]GHHHI#"BBB@
M`HK@?B!J%[97UFMK>7$"M$21%*R@G/L:Y:+Q1KD(4+J=P=IR-[;OSSG-.PKG
ML]%>0_\`":^(?^@A_P"08_\`XFK`\>ZZ`!YL)]_*%%@N>K45Y0_CS764@30J
M3_$(AD?G59_&7B"1"K:BP!_NQHI_,"BP7/8**\4D\0ZS(VYM4O`?]F9E'Y`U
MZ%X"N[F\T*>2ZN)9W%RRAI7+$#:O&3]:+!<ZFBBN*^($M]!_9TUF]Q'L\W>\
M)8;?N]2/Q_6D,[6BO%HO$FM1`A=4NCG^](6_G5I?&GB!5"C4#@#',2$_GMIV
M%<]?HKR'_A-?$/\`T$/_`"#'_P#$U#-XLUV?._4I1D8^0!/_`$$#\Z+!<]DH
MKS#P?<:M?^([66:>]N+:+?O=W9T7*'&2>!SBO3Z0PHHHH`***\[^(VI"2YMM
M-0\1#S9.>,G@#Z@9_P"^J`/1**\$C=HI%D1BKJ0RL.H(KVS1=175='MKT?>D
M3YQZ,.&'Y@T"3+]%%%`PHHHH`****`"BF3>9Y,GE8\S:=N>F>U>2?\)KXA_Z
M"'_D&/\`^)H%<]>HKR(>-O$((/V_/MY,?_Q-7(_B'K*+AHK.0_WFC;/Z,*=@
MN>HT5YPOQ(O0HW6%N6QR0S`9J.7XCZD2/*L[11WW!F_J*+!<]+HKRN7X@:W(
M<K]FBXQA(_UY)K8\&>(-6U?6I(+V\\R)(&DV^6@R<J.H`/>BP7.\HHK@O%'B
M[4=+UV6SLY(O+C5<AH\D$C/7\12&=[17E/\`PGVN?\](/^_0H_X3[7/^>D'_
M`'Z%.PKGJU%>8#XBZP`!]GLC[E&_^*J.7X@ZU(056UCQV6,\_F318+GJ=%>?
M^$/$NK:GKJVUY=>;"8V.WRU7D>X`KT"D,****`"BBB@`HHHH`****`"BBB@#
M(\4_\BOJ'_7(_P`Z\9KV;Q3_`,BOJ'_7(_SKQFFB6%%%%,1Z=\.?^1>N/^OI
MO_0$KKZXOX;R$Z3=Q8&U9]P]<E1_@*[2I+04444`%%%%`!1110!XYXJTI=(U
MZ:",8AD_>Q#T4]OP((_"L6O1OB/9;[&TOE',<AC8CT89'ZC]:\YIDL*N:5J$
MFE:G!>Q=8FR1_>'<?B*IT4Q'O4,R7$$<T;;HY%#J?4$9%/KE_`5_]K\.B!C\
M]LYC_P"`GD?S(_"NHJ2R&XL[6[7;<VT,P])$#?SKA/%W@Z&WMFU'2XMB1C,T
M(R0!_>'T[BO0:"`001D'J#0!X%170^+]"_L75=T*XM+C+Q8Z*>Z_A_(USU40
M%>CZ9X$T>YM(;HW5S<)*H=<$("".XP3G\:\XKNO`&N^5*VD7#`(Y+P,3T;NO
MX]?S]:3&CK;#PSH^FR)+;62"5>DCDL0?7D\?A6M112*"BBB@"K>:;9:@`+RT
MAGP,`R("1]#VKF/$/A?0++1;N\6W,$B(61DD;ES]T8)(QDBNQKS/Q[K9N[\:
M9"W[FV.9,'AG_P#K?U-`F<>B-(ZHBEF8X"@9)/I7H&B_#Z(P1SZM(YD89,$9
MP%]B>_X8IG@'0/\`F,W*>JVZG\BW]!^/M7?TVP2*.GZ-I^E;OL-JD)8`,1DD
MCZGFKU%%(9FW>@:3?%FN-/MV=R2SA-K$GN2.:Y[5?A[931.^FR/;R@?+&[;D
M/MSR/KDUV=%`'A-Y9W&GW<EK=1F.:,X93_/Z5!7H'Q)M$V6-X%P^6B8XZCJ.
M?;G\Z\_JB0K2T76KK0[X7%N<J>)(R?E<>A_H:S:*!'M^E:K:ZS8K=6KY4\,I
M^\A]#5ZO%-%UJZT.^%Q;G*GB2,GY7'H?Z&O7=*U6UUFQ6ZM7RIX93]Y#Z&I*
M3+U%%%`PHHHH`R;OPSHMZQ:?3H=QZE`4)_[YQ7,Z]X#LX-/GO-/EE1X4,AB<
M[@P`R0#U!_.N\JO?_P#(/N?^N3?R-`K'A5>@^&_`UM):0WVIGS?-0.D"D@`$
M9&3US[?SKSZO;M$8MH&G,Q)8VL1))Y)VBFQ(EL]-LK`8M+2&#(P2B`$_4]ZM
M444B@HHHH`****`"L7Q7J1TOP]<RH<2R#RH^<<MQD>X&3^%;5>;?$34?.U*#
M3T(VVZ;WP?XF['Z`#\Z!,XNBBBJ)/7_!^J#4_#T&YLS0#R9,]>.A_$8Y]<UO
M5Y;X"U3[%K9M'/[J[&WKT<<C^H_$5ZE4E(****!D-Q:6UVFRYMXIE_NR(&'Z
MUC:AX.T6^B8+:+;R'.V2'Y<'Z=/TK?HH`\-U+3YM*U":RN`/,C.,CH1V(JI7
MH?Q$T@R0PZM$.8\13?[I/RG\SC\17GE,EA75^#/#5KK;3W%ZS-#"P41*<;B?
M4^GTKE*ZOP#J7V/73:N<1W:;?^!#D?U'XT`CT2#1M,MAB'3[5.,9$2Y/U/>K
MU%%(H****`*UQI]E=AOM%I!+NZ[XP<_G7F?C70K/1KRW:R^1)U8F(MG:01R.
M^#G]#7JM>2^-]0^W>))45LQVP$*\\9'+?J2/PIH3,"""6YN(X(4+RR,%11W)
MKT_2/`NFV*))>+]KN!@G?]P'V7N/K7/_``]TK[1J,NI2#]W;C8GNY']!_,5Z
M50P2&QQI%&J1HJ(HP%48`%.HHI#"BBB@!LDB11M([!44%F8]`!7B&JW[ZGJE
MS>OG,KE@#V'0#\!@5Z9XXU+[!X>>)&Q+='RACKM_B_3C\:\GIHEA7=_#K5-D
MMQIDC</^]BR>XX8?E@_@:X2K>F7TFF:G;WL>=T+AB!W'<?B,C\:8'N5%,AF2
MX@CFC;='(H=3Z@C(I]24%%%%`!1110`5DS^&-$N,[],MQD8_=KL_]!Q6M10!
MY_K_`(!2&WDNM)=R4&YK=SG([[3_`$/Y]JX*O?:\O\;^'O[.O/[0MU_T6X;Y
M@!_JW]/H>3^?M30FCDJ***9)Z3X:\,>'[_1[:\,+7$C*/,WR'Y7'WA@8XSZ]
ML5U5GIECI^?LEI!`2,$QH`2/<]37F?@O7_[)U+[/.^+2Y(#9Z(W9OZ'_`.M7
MJU)E(*R]0\.Z3JLXGO;,22@8W;V4X_`BM2BD,Y:^\$^'UM99?*DMEC0LSI*3
M@`9S\V:\KKT#Q]KX"?V/;L"3AK@@].X7^OY5Q6FZ=/JM_%9VRYDD.,GHH[D^
MPIHEEK0M`N]>NS%!\D:<R3,/E3_$^U=]:_#_`$:``S^?<GOO?:/_`!W'\ZV]
M(TFVT;3X[2W4<#+OCEV[DU?HN.Q2LM'T[3B&M+*"%\8WJ@W8]-W6KM%%(844
M44`%%%%`!1110`4444`%%%%`&1XI_P"17U#_`*Y'^=>,U[-XI_Y%?4/^N1_G
M7C--$L****8CT;X;?\@^^_ZZK_*NWKB_AO&PTJ\D/W6G"CZA1G^8KM*EE(**
M**!A1110`4444`8/C.W%QX5O.FZ,+("3TPPS^F:\@KVOQ`BR>'=25AD"VD;\
M0I(_45XI31+"BBBF([7X;W)35+RVSQ)"'_%3C_V8UZ17DW@641^*K=2,^8CJ
M/;Y2?Z5ZS292"BBBD,S==TB+6]*ELY,!C\T;G^%QT/\`3\:\8G@EMKB2"9"D
ML;%74]B*]YKAO'OA_P`Z/^V+9,R(`+A0.J]F_#H?;'I30FCSNE1VC=71BK*<
MA@<$'UI**9)[#X6UY==TL.YQ=0X6=??LWT./YUN5XOX>UE]#U:.Z`W1'Y)5]
M5/7\1UKV6&:.X@2:%P\;J&5AT(-2RD/HHJ.>>*VMY)YG"11J6=CV`H&97B;7
M%T/2FE!!N9,I"I&?F]?H*\QT#1Y=>U=8"6\O.^:0\X7OSZFEUW5Y_$.L&54;
M:2(X(NX&>/Q->F^&=#70]*6(@&YDP\S`Y^;T^@IBW-:&&.W@2&%`D:*%51T`
M%/HHI#"BBB@`HHHH`Y#XC?\`(O6__7TO_H#UP.C:3+K5\;2&14D\MG7=T)';
MVKOOB-_R+UO_`-?2_P#H#UR7@AV3Q;:*IP'$BM[C83_,"F2]S#N;::TN)+>X
MC:.6,X96Z@U%7L/B+PU;:];$X6*\4?NYL?HWJ/Y5Y/?Z?=:9=M:WD1BE7G![
MCU![B@&BM6EHNM76AWPN+<Y4\21D_*X]#_0UFT4Q'M^E:K:ZS8K=6KY4\,I^
M\A]#5ZO%-%UJZT.^%Q;G*GB2,GY7'H?Z&O7=*U6UUFQ6ZM7RIX93]Y#Z&I*3
M+U%%%`PHHHH`\$D1HI&C<8925(]"*]KT+_D7M-_Z]8O_`$`5X[JD9AU:]B8@
MLD[J<=,AC7L.@L&\.Z:5((^RQC@]PHILE&C1112*"BBB@`HHHH`CGFCMK>6>
M4XCB0NQ]`!DUX=?7<E_?3W<OWYG+D>F>U>E>/M2^QZ$MJIQ)=OM_X".3_0?C
M7G.E6#ZGJEM9)G,KA21V'4G\!DTT)E1E*G#`@X!Y'8TE=M\0-'6UGMM0@C5(
MG40N%'1E'R_^.C'_``&N)IB'Q2R03)-$Q22-@RL.H(Y!KV[2K]=3TNVO4QB5
M`2!V/0C\#FO#J[_X=:IQ<:7(W_3:+)^@8?R/YTF".^HHHI%!1110!!>6L=]9
M3VLH_=S(4/MD=:\0O;22PO9K2;_61.4..^.]>[5YQ\1-+,-]#J2+\DX\N0C^
M^.F?J/\`T&FA,XFI()I+:XBGB.V2)PZGT(.14=%,D]TT^]CU'3[>\B^Y,@<#
M.<>H_#I5FN'^'>J&6UGTN1LM%^]B'^R3R/S.?^!5W%26%%%%`%>^NEL;"XNG
M(VPQL_/?`Z5X9)(\TKRR-N=V+,?4GK7IGQ!U(6VCQV*-^\NF^8?["\_SQ^M<
M;X2TW^T_$5O&PS'%^^D^B_\`U\"FA,],\.:9_9.A6UJ1B7;OE_WSR?RZ?A6K
M112&%%%%`!11574;V/3M.N+R3[L*%L>I[#\3@4`>:>.]2^VZ^;=&)BM%\L#M
MN/+'^0_"N7P<9QQZT^662>9YI6+R2,69CU)/)-=]/X8_XM]$JQ@WD8^U\#DY
MY(_[YP/JHID[GGU%%%,1Z?\`#_5!=:,UB[9EM6X![H>1^N1^5==7COA35?[)
MUZ"5SB&7]U+[`]_P.#7L5)E(****0PHHHH`****`"H+RTAO[.6UN%W12KM85
M/10!XGK>DRZ+JDMG(2P7YHW(QO4]#_3Z@UG5ZSXQ\/G6M-$L"YO+?+1C^^.Z
M_P!1[_6O)B""01@CJ*9+"O2O`_B/[;;C2[I_](B7]RQ_C0=OJ/U'TKS6I;:X
MEM+F.X@<I+&P96'8B@#WBLCQ'KD>A:6TYPT[_+#&3]YO7Z#K_P#KI-)\0VFH
M:%_:4LB0B,8N`>B,.OY]OJ.]>8^(]<DUW5&G.5@3Y88R?NKZ_4]?_P!5`VS-
M=YKRZ9W+RSRODGJ68FO6/"GAU=#L-TRJ;V89E8<[1V4'^?O6)X&\->6BZO>1
M_.PS;HPZ#^_^/;\_2N[H8)!1112&%%%%`!1110`4444`%%%%`!1110`4444`
M9'BG_D5]0_ZY'^=>,U[-XI_Y%?4/^N1_G7C--$L****8CT[X<_\`(O7'_7TW
M_H"5U]<?\.74Z#<H#\PN22/8JN/Y&NPJ2T%%%%`!1110`4444`9^N_\`(O:E
M_P!>LO\`Z`:\2KV?Q/-Y'AG47W`9A*9/^UQ_6O&*:)84444Q'0>"03XNLL#I
MYF?^^&KUVO+/A]&7\2E@1B.!V.?3(']:]3I,I!1112&%(Z+(C(ZAD8892,@C
MTI:*`/&_$VAOH>JM$`3;29>%B<_+Z'W%8U>S^(=%CUS2GMC@3+\T3_W6_P`#
MTKQN:&2WG>&9"DB,593U!%-$L97H/P_UW<K:/._*Y>W)/4=2O\S^=>?5)!/+
M;7$<\+E)8V#(P[$4P/>:\U\<^(OMEP=+M7S;Q-^]8'[[CM]!_/Z5?U3QRDGA
MN(VC;-0G!1PO_+''4_CV_P#K5S7A70#KFIA9`PM(OFF8=_1?Q_QI#;.A\!^'
M>FL72^UNI_5C_3\?:N_I$18T5$4*BC"J!@`>E+2&%%%%`!1110`4444`<M\0
M$5_#.YADI.C+['D?R)KBO!7_`"-UC_VT_P#1;5V_C[_D6'_ZZI_.N(\%?\C=
M8_\`;3_T6U,3W/7JR=>T"UUZS\J;Y)5YBF`R4/\`4>U:U%(9XAJNE76CWS6M
MTF&'*L/NN/451KVO6M%M=<L3;W`PPYCE`^9#ZC^HKR+5=*NM'OFM;I,,.58?
M=<>HIDM%&M+1=:NM#OA<6YRIXDC)^5QZ'^AK-HIB/;]*U6UUFQ6ZM7RIX93]
MY#Z&KU>*:+K5UH=\+BW.5/$D9/RN/0_T->NZ5JMKK-BMU:OE3PRG[R'T-24F
M7J***!GB6N_\C#J7_7U+_P"AFO5?"C!O"^GE2"/*QP>X)KRWQ#&8O$>I*Q&3
M<.W'H23_`%KTOP5_R*-C_P!M/_1C4V2C?HHHI%!1110`4451UC4!I>D75Z1D
MQ)E1ZL>!^I%`'F?C;4O[0\12QJ?W=M^Y7ZC[WZY'X5K?#G3?,NKG4G7Y8QY4
M9/\`>/)_3'YUP[,68LQ)8G))/)->S>&]-_LK0;6V9<2[=\GKN/)S].GX4R42
M:]IO]K:)=68`,CIF//9QR/IR,?C7BA!!((P1U%>^UY%XSTW^SO$4Y12(;C]\
MGX_>_7/Z4(;.?JYI5^^EZK;7J=8GR1ZCH1^()JG13)/>XI$FB26-MR.H93Z@
M]*=7+>`]3^W:"+9VS+:-L_X">5_J/PKJ:DL****`"LOQ%I@U?0[FU'^LV[XS
MCHXY'Y]/QK4HH`\"(()!&".HHKH/&6E?V9K\I10(;C]ZF.V>H_//Z5S]407]
M%U)])U>WO$/"-\X_O*>"/RKVR.1)8UD1@R,`RL.A!KP2O4O`>J_;M%-I(?WM
MH=@]T/W?ZC\!292.KHHK/UO41I6C75X3AHT.SC/S'A?U(I#/,?&.HG4?$=QA
MLQ0?N4Q[=?US76_#W3?L^DRWSKA[E\+D?P+_`(G/Y"O.;6WDO;V&WCYDFD"#
M/J3BO<;.UCLK.&UA&(XD"+^`IL2)J***0PHHHH`*XCXBZEY5E;Z<A^:9O,D_
MW1T'XG_T&NWKQGQ/J7]J>(+J=3F)6\N/_=7C/X\G\::$QGAS3O[5UZUMB`8]
M^^3(XVKR1^.,?C7M)`(((R#U!KA?ASIVRWNM2<#,A\F/CD`<G\SC\J[JA@CQ
M7Q!IO]DZY<V@'[L-NC_W3R/\/PK,KT3XC:;YEK;:DB_-&?*D(_NGD?KG\Z\[
MH$PKV/PIJ?\`:OAZWE8YEC'DR?[R]_Q&#^->.5V'P]U/[-JTM@[?)=+E?]]>
M?U&?R%#!'IM%%%(H****`"BBB@`HHHH`*\V\=>'OLEQ_:MJF()3B90,!']?H
M?Y_6O2:CG@BN;>2"9`\4BE74]P:`/!J*U_$FB2:%JKP?,;=_GA<]U]/J.GZ]
MZR*H@>LTJ121+(RQR8WJ#PV.F:Z3P?X;.L7GVFY7_086^8$?ZQO[H]O7_P"O
M7,5V/@;Q#]BNAIET_P#H\S?NB3]QSV^A_G2&CTP````8`Z`4444B@HHHH`**
M**`"BBB@`HHHH`****`"BBB@`HHHH`R/%/\`R*^H?]<C_.O&:]F\4_\`(KZA
M_P!<C_.O&::)84444Q'HWPV_Y!]]_P!=5_E7;UQ_PY4#0+AL#<;I@3CG&U?\
M3785+*04444#"BBB@`HHHH`Y?Q]<^1X9:+O/*B?E\W_LM>55V_Q'OA)?6EBI
M_P!4AD?ZMP/T'ZUQ%-$L****8CO_`(;6AVW]X<[25B7TSU/\UKOJR/#.FG2M
M`MK=UVRE?,E!Z[FYP?IP/PK7J2T%%%%`!1110`5Q/CSP\MQ;'5[9`)HA^_`_
MC7IGZC^7TKMJ;)&DL;1NH9&!5E/0@T`>"45)<1"&YEB!R$<J#ZX-1U1`5[/X
M<TR'2]$MX8@-SH))&_O,1R?Z5XQ7NMA_R#[;_KDO\A28T6****104444`%%%
M%`!1110!RWQ`=4\,[6."\Z*ON>3_`"!K@O"W_(SZ?_UU'\J[?XC?\B];_P#7
MTO\`Z`]<1X6_Y&?3_P#KJ/Y4T2]SV:BBBD4%9NM:+:ZY8FWN!AAS'*!\R'U'
M]16E10!XAJNE76CWS6MTF&'*L/NN/451KVO6M%M=<L3;W`PPYCE`^9#ZC^HK
MR+5=*NM'OFM;I,,.58?=<>HIDM%&M+1=:NM#OA<6YRIXDC)^5QZ'^AK-HIB/
M;]*U6UUFQ6ZM7RIX93]Y#Z&KU>*:+K5UH=\+BW.5/$D9/RN/0_T->NZ5JMKK
M-BMU:OE3PRG[R'T-24F>5>+HS%XJOU8@DN&X]"H/]:]"\$.K^$[15.2AD5O8
M[R?Y$5P7C7_D;K[_`+9_^BUKM_`/_(L)_P!=7_G3!;G3T444AA1110`5P7Q&
MU+"6NFHW4^=(!^2C^?Y"N])`!).`.I->*:_J)U77+J[SE&?$?^X.!^@S^--"
M97TV6V@U*VFO%=[>.0,ZH`2P'.,&O2D\?Z(R@DW"D_PF+D?D:\\M=!U6^MUN
M+:QFEA;.UU'!QQ4W_"+:Y_T#)_R%`CO_`/A/M#_YZ3_]^C7->,==TG7+2W:U
M>3[3"YQNC(!4]?Y"L7_A%M<_Z!D_Y"C_`(1;7/\`H&3_`)"@-3(HJ2>"6VG>
M">-HY4.UE88(-1TQ'2^!]2-AXACB8XBNAY39/?JI^N>/QKUBO`T=HW5U.&4Y
M!]#7MNC:BNK:1;7J]9$^8>C#@C\P:3*1?HHHI#"BBB@#FO&^E?VCH331INGM
M3YBXZ[?XA^7/X5Y/7OC*'4JP!4C!!'!%>+>(-+.D:U<6@!$8;=$3W0\C_#\*
M:$S,K;\*:K_9.O02N<0R_NI?8'O^!P:Q**9)[[7!_$?4=L5KIJ$Y8^<_/;D*
M/SS^0K?\)ZL-4\/PR2-F6']U*6]0.OXC!_.O,O$&I?VMKES=@_NRVV/_`'1P
M/\?QI(IF[\/M-^TZO)?.I,=LGRGMO;C\>,_I7IM87A#3?[-\.VZLN)9AYTGX
M]!^6*W:0(****!A1110!C^*=2_LOP_<S*P65QY47^\W''T&3^%>-5VWQ$U+S
M;^#3D8%8%\R0#^\>@/X<_P#`JY2QTR]U)G6SMGF*`%M@Z4T2SN]%\9Z)I^E6
M]EMN8_)C"DF(89NI(P3WR?QK0_X3[0_^>D__`'Z-<!_PBVN?]`R?\A1_PBVN
M?]`R?\A0%V=EJ_B_0=3TFZLR\V98R%S%T;J#^>*\VK7_`.$6US_H&3_D*IWV
MF7NFLBWEL\)<$KO'6@"I4UI=265Y#=0G$D3AU_`U#13$>[VES'>6<-S$<QRH
M'7Z$9J:N.^'NJ?:=*DL';]Y;-E/]QN?YY_,5V-26%%%%`!1110`4444`%%%9
M/B'7(M"TUKAL-,WRPQG^)O\``=__`*]`'-_$/4;,VT6G[%DNPPD#`_ZH?_7]
M/Q]*\\JTQN]6U'/SSW5P_P"+$_Y_"NPUKP,+30(I[0F2\@7,X!SY@[X^G\O>
MF3N<+1113$>K^#?$/]L6'V>X;-Y;@!B?XUZ!OKZ__7KIJ\,TW4)]+U"&\MSB
M2)LX/1AW!]B*]ITW4(-4T^&\MSF.5<X/53W!]P:3*3+5%%%(84444`%%%%`!
M1110`4444`%%%%`!1110!D>*?^17U#_KD?YUXS7LGBQU3PMJ!8X'EX_$D`5X
MW31+"BBBF(]+^'$H.C746.5N-V?JH']*[*O,?A]J26NL2V<AP+M`%/\`M+D@
M?D37IU2RD%%%%`PHHHH`*CN)X[6VDN)FVQQJ78^@%2$@`DG`'4FO-O&?BI+_
M`/XEVGR[K8<RR+T<^@]J`.7U6_?5-5N;U^LKY`]!T`_``53HHJB`KI?!>BG5
M-96>1<VUJ1(^?XF_A'YC/T%8NF:=<:K?Q6ELFYW/)[*.['V%>R:1I<&C:;%9
MP<A>68]78]328TB]1112*"BBB@`HHHH`****`/"K[_D(7/\`UU;^9JO5B^_Y
M"%S_`-=6_F:KU1`5[XB+&BHHPJC`'H*\#KWVDRD%%%%(84444`%%%%`!1110
M!R'Q&_Y%ZW_Z^E_]`>N(\+D#Q/I^3C]\*[?XC?\`(O6__7TO_H#UP.A?\C#I
MO_7U%_Z&*:)>Y[;1112*"BBB@`K-UK1;77+$V]P,,.8Y0/F0^H_J*TJ*`/$-
M5TJZT>^:UNDPPY5A]UQZBJ->UZUHMKKEB;>X&&',<H'S(?4?U%>1:KI5UH]\
MUK=)AARK#[KCU%,EHHUI:+K5UH=\+BW.5/$D9/RN/0_T-9M%,1K^)KZWU/6Y
M+ZV9BDZ(Q5A@J0H!'Z5WGP_D5_#6T=4G=3]>#_45Y97IWPY_Y%ZX_P"OIO\`
MT!*3&CKZ***104444`8/C'4O[-\.SE6*S3_N8\>_7],_I7DD$,ES<101#=)*
MX11ZDG`KK/B#J7VG5X[%&)CMD^8=M[<_CQC]:A\`Z=]LU[[2P/EVB;^G!8\`
M?S/X4R7N>EV-I'86$%I%]R%`@/KCO5BBBD4%%%%`'FWQ#TSR-2AU%!\EPNQ_
M]]>GYC'_`'R:XNO9O$^F?VMH%S;JFZ91YD7'.X=A]1D?C7C--$L*[WX<ZGA[
MG3';@_OHOKT8?R_(UP57]&U`Z7K%K>`G;&XW@=U/!'Y9I@CVZBD5@ZAE(*D9
M!!X(I:DH****`"N,^(6E?:-.BU*,?O+<[']T)_H?YFNSJ*YMX[NUEMY1F.5"
MC#V(Q0!X/15G4+*33=0GLY>7A<J2._H?Q'-5JH@T],UJXTRRU"VB^[>1;"?[
MISU_(L/Q'I2^'=,_M;7;:U(S'NWR_P"X.3^?3\:RZ]$^'.F^7:W.I.OS2'RH
MR?[HY/ZX_*D-'<T444B@HHHH`*9-,EO!)-(VV.-2['T`&33ZY;QYJ7V+0?LR
M-B2[;9[[1RW]!^-`'FFHWCZAJ-Q>2?>FD+X]!V'X#BO3/`FF_8M`%PZ@2W;>
M83WVCA1_,_C7F>GVCW^HV]HG#32!,^F3UKW&&%+>".&-=L<:A%'H`,"FQ(?1
M112&%<SXYTS[?X?>95S+:GS1C^[_`!?IS^%=-2.BR(R,,JPP1ZB@#P.BKVLZ
M>VE:O<V;=(W.T^JGD'\L51JB#9\+:G_97B"WF9L1.?*D_P!UO\#@_A7LE>!5
M[/X9U+^U=`M;AF+2A?+E)Z[AP3^/7\:3*1K4444AA1110`444$@`DG`'4F@"
M"\O(+"TENKF01PQC+,:\<UW6I]<U)[J7Y4'RQ1YR$7_'UK5\8^)?[8NA:VK'
M[%">#_ST;^]]/2CP?X:.L7?VJY3_`$&%N0?^6C?W?IZTR7J=#X%\._8[<:I=
M)B>4?N5/5$/?ZG^7UKM*````!@#H!12*/+?&GAS^RKO[;;)BSG;D#_EF_I]#
MR?TKE*]WN[2&^M);6X3?#*NUEKQG6](GT34I+2;E>L;XX=>QIHEHSJZ?P9K_
M`/9.H_9IWQ:7!`;/\#=F_H?_`*U<Q13`]]HKD/`VO_;[+^SKA\W-NOR$_P`<
M?^(Z?3'O77U)04444`%%%%`!1110`4444`%%%%`!4<]Q!:Q&2XFCBC'\4C!1
M^9KS'Q1XCU=-;O+2*^EB@BDVHL7R$#CN.?UKEY9I9WWS2O(W]YV)/ZT["N=M
MXS\56M_:?V;I\AD0L&EE&0IQ_"/7G!KAJ**8@HHHH$*CM&ZNC%64Y#`X(/K7
MH.@^/XV1;?6!M<8`N$&0?]X=C[C\A7GM%`SW6UOK2^0/:W,4RXS^[<''U]*L
M5X%5C[=>?\_4_P#W\-*P[GNC,$4LQ`4#))/`%8NI^+-(TL$/=+-+CB*#YS^)
MZ#\37D$LTLQ!EE>0CH68G%,HL%SH]=\8W^LJT$?^BVIX,:'EQ_M'O].E<Y14
MUK:7-[,(;6"2:0_PHI)IB(:T-(T6]UJZ$%I'D#[\AX5!ZD_TZUU&C?#Z>4K-
MJTGE1]?)C.6/U/0?K^%=]:6=M86ZV]K"D42]%44KA8HZ%H%IH-H8H/GE?F29
MA\S_`.`]JU:**104444`%%%%`!1110`45Q=U\1[&/(M;*>8CNY"`_P`_Y5BW
M7Q$U27(MX+>`'O@LP_/C]*+"N<Q??\A"Y_ZZM_,U7ITCM+(TCG+,2Q/J33:H
MD*]]KP*NRLOB'>6T$44UE!*(U"Y5BI(`Q[\TF-'I=%<1;?$BTD=1<V$L()P6
M1P^!Z]!7;TB@HHHH`****`"BL;Q!XBM_#\4#31/*TS$*JD#@=3^HK!_X639_
M]`^?_OL4!<F^(\BC0[6/^)KD,/H%;/\`,5YW8R>5J%M)OV;)5;=G&,$<YK9\
M3^*&\0&&-+?R((22`6W%B>Y]/I7/4R6>^T5YO9_$:[AA2.YL8YRJ[2RR%2Q]
M3D&M!/B3:D+YFG3*>X60''\J5AW.XHJ&TN4O+."ZC#!)HUD4-U`(R,_G4U`P
MHHHH`*S=:T6UURQ-O<###F.4#YD/J/ZBM*B@#Q#5=*NM'OFM;I,,.58?=<>H
MJC7M>M:+:ZY8FWN!AAS'*!\R'U']17D6JZ5=:/?-:W288<JP^ZX]13):*->G
M?#G_`)%ZX_Z^F_\`0$KS&O3OAS_R+UQ_U]-_Z`E#!'7T45#=W*6=G/=2!BD,
M;2,%ZD`9./RI%$U5[Z\BT^QFNYCB.)"Q]_:N&NOB3(<BTTY5]&EDS^@`_G7-
M:QXEU+7%$=U(BPJ=PBC7"Y]?4_B:=A7,Z[N9+R\FN93F25R[?4G->G>`;-;?
MPXMP`-]S(S$]\`[0/T/YUY76UH_BG4]$C\FVD1X,D^5*NY0?;H1^=`D>QT5Y
M]!\2I!@7&FHW(R8Y2,#OP0?YUZ#2*"BBLC7]?@\/VT4LT,DOFMM4)@?GF@#7
MKQSQ7IG]E>(;B)1B*0^='_NMV_`Y'X5M7?Q'OI!BTLX(,]W8R'^@_2N5U#4;
MK5+IKF\E,DI&,D8P/0`4T2V5:***8CU7P+JPO]$%J[?OK3"')ZI_"?Z?A745
MX;IVIWFDW/VBRF,4F,'@$$>A!X-=1;?$?44(^TV=M*H'.S*$_CDC]*5BDSTJ
MBJNFWRZEIT%XB%%F7<%)Y%6J0PHHHH`\Z^(NF^7=V^I(IVRCRI#VW#I^8S_W
MS7#U[1XCTT:KH-U;`9DV[X\#)WCD?GT_&O%Z:)8^&%[B>.&-=TDC!%`[DG`K
MW#3K&+3-.@LH?N0H%SZGN?Q.3^->9>!=/^V^(TE89CME,ISZ]!^IS^%>KT,:
M"BBBD,***X_6O'D>F7T]G#8O+)$=I9W"C/X`Y_2@#L*\E\:ZHNI>('6)@T-L
MOE*0>">I/YG'X5)J'CK5[Z)XHS%;1L,'RE.['U/],5S%-$MG8?#NT2;6YKEL
M$P1?*/=N,_EG\Z]-KP[3=4O-(NOM%E+Y;XP>`0P]"#756_Q(O4"BXL8)<==C
M%,_GFAC3/1Z*S="U==;TQ+U83%EBI0MG!'O6E2&%%5[Z\BT^QFNYMWEPH68*
M,D^PKAKKXDR'(M-.5?1I9,_H`/YT!<7XCZ:`;74D`!8^3)[GDK_[-^E<%6KK
M'B/4M;"K=RKY2MN6)%PH/\S^)K*IDL*[+X?:L+74I-.E;$=R,QY/1QV_$?R%
M<;2H[1NKHQ5E.0P."#ZTP/?**\MM/B!K$"JLRV]P!U+H0Q_$$#]*[7PUXD7Q
M%#.?LY@D@*[EW;@<YP0<#T-2.YNT45Q4WQ(L%SY%C<OQQO*KS^&:!G:UY[XU
M\5>89=(L6^0?+/*#][_9'MZ_E]<_5?'NHW\+0VT:6<;`@E#N?'^]V_`5RE.P
MFR>RM)+^]AM(?]9*X09[9[U[=864.G6,-I`N(XEVCW]3]2>:\+1VC=71BK*<
MA@<$'UKK-.^(&J6H5+N..[0#&6^1_P`QQ^E#$CU"BL30O%%EKSO%`DD<R+N9
M)`.G3((//6MND4%8'BS0EUK26,:9NX`7B(')]5_'^>*IZGX]L+"YGMH[:>:>
M%V1NBKD9!YZ]1Z5@7?Q&U"566UM((,]&8ER/Y#]*8KG&44K,68L3DDY-)3))
M[.[FL+R*ZMVVRQ-N4U[)H>LV^N:<ES"<..)8^Z-W'T]#7BE7M+U>]T>X,]E,
M48C#*>58>XI#3/;Z*\_L_B2V`+[3P3W>!\?^.G_&NXL;R+4+&&[AW>7,@90P
MP1[&D5<L4444`%%%%`!1110`4444`<S?^!M,U&_FO)I[M9)6W,$=0`?;*U77
MX=:.&!,]ZP!Z&1<'_P`=KKJ*`L<TG@/0D<,T$K@?PM*<'\L5-_PA7A[_`*!_
M_D:3_P"*K?HH"Q@?\(5X>_Z!_P#Y&D_^*H_X0KP]_P!`_P#\C2?_`!5;]%`&
M!_PA7A[_`*!__D:3_P"*I#X)\/$$?8,>XFD_^*KH**`.8_X0'0_^><__`']-
M0O\`#O1G<LLUX@/\*R+@?FIKK:*`L<A_PKG2/^?F^_[[3_XFGQ_#S1D;+27<
M@QT:08_117644!8P[;P?H5L05L$D8=Y6+Y_`G'Z5L0P0VT8C@B2)!T5%"C\A
M4E%`!1110`4444`%%%%`!1110`4C*'4JP!4C!!'!%+10!R'_``KG2/\`GYOO
M^^T_^)J6/X?:*BX8W4ASU:09_0"NJHH"QS'_``@.A_\`/.?_`+^FIQX)\/``
M?8,^YFD_^*KH**`L<T_@/0G<LL$J`_PK*<#\\U3D^'&EE?W=W>*WJQ5A^6T5
MV-%`6.,A^'=I#/'*+^8E&#`;!S@UV=%%`!1110`4444`87B7PVOB**W7[3Y#
M0LQ#>7OR#CCJ/05A1_#6`+^]U*1FSU6(*,?F:[JB@+''I\.=*"`/=7I;N0R@
M?EMI?^%<Z1_S\WW_`'VG_P`377T4"L<2_P`-[(EO+O[A1V#*IQ_*J_\`PK/_
M`*B__DM_]G7?447"Q7L;;[%I]M:;]_D1+'NQC=M`&<?A5BBB@84444`%%%%`
M!65K^A6^O6'D2G9*F6BD'\!_J/:M6B@#R-_!'B!7918A@#@,)DP??DYKN?!>
MEWFDZ/-!?0^5*UPSA=P;C:HSP3Z&NCHHN*P5#=VR7EG/:R%@DT;1L5Z@$8./
MSJ:B@9R'_"N=(_Y^;[_OM/\`XFKL'@?086W&U>4Y!'F2M@?@"/UKHJ*`L83^
M#?#\CEFTY03_`'9'4?D#4,O@;0)``MH\>.Z3-S^9-='10%CF/^$!T/\`YYS_
M`/?TUT]%%`!65K>@6NO0Q174DR+$Q9?*(!S^(-:M%`'+CP#H8`&R<^_FU+%X
M%T"/.ZUDDS_?F;C\B*Z.B@+&!_PA7A[_`*!__D:3_P"*I&\$^'RI`L"I(ZB9
M\C_QZN@HH`Y9_A_HCH547*$_Q+)R/S!J'_A7.D?\_-]_WVG_`,377T4!8J:9
MI\.E:?#96Y<Q1`X+G).22<_B:MT44`%%%%`!7`ZA\/9KG4;B>"\BCBED+JC*
M25R<XKOJ*`,'POX=_P"$?M9U>999IG!9E&``!P/U/YUO444`%%%%`!7,7_@;
M3-1OIKR:XO!),Q9@KJ`/I\M=/10!R\/@#0XL;UN)L'^.7&?^^0*N-X.T!D5#
MIR87IB1P?Q.<FMRB@+'/MX)\/E2!8%21U$SY'_CU0?\`"`Z'_P`\Y_\`OZ:Z
M>B@+%/3-,MM)LEM+166($M\S9.35RBB@"M?V4>HV$UG,SK'*NUBA`('MFN>C
M^'^B(N&^TR'^\TG/Z`5U5%`',IX#T)6!,,S`?PF4X/Y5/_PA7A[_`*!__D:3
M_P"*K?HH"Q@?\(5X>_Z!_P#Y&D_^*J!_`>A,Q(AF4'^$2G`_.NFHH"QR)^'6
MCDD_:+T>V]/_`(FM?0_#EGX?\_[))._G[=WFL#C;G&,`>IK7HH`*XC_A6UG_
M`-!"?_O@5V]%`'')\.-+"`275XS=RK*!^6TU/'\/M%1<,;J0YZM(,_H!7544
M"L<L_P`/]$="JBY0G^)9.1^8-5I/AQIA7]U=W:MGJQ5AC\A7944#L<[H'A*W
MT&]DNHKF65GC,>&```)!_I71444`<M=^`M+O+R>ZDN+P/-(TC!77`).3CY?>
MH?\`A7.D?\_-]_WVG_Q-=?10%CEQX!T,`#9.??S:L#P3X>``^P9]S-)_\570
M44!8YB3P#H;[ML<Z9SC;*?E^F<_K55_AQI90B.ZO%;L692/RVBNQHH"QQ'_"
MMK/_`*"$_P#WP*["RM5L;"WM$.Y88UC!(QG`QFIZ*`"BBB@`HHHH`****`"B
MBLCQ1KG_``C?AVZU;[/]H^S[/W6_9NW.J]<''WL]*<8N345NQ2DHIR>R->BO
M(O\`A>'_`%+O_D[_`/:Z/^%X?]2[_P"3O_VNNOZAB/Y?Q7^9R_7L/_-^#_R/
M7:*\B_X7A_U+O_D[_P#:Z/\`A>'_`%+O_D[_`/:Z/J&(_E_%?YA]>P_\WX/_
M`"/7:*\B_P"%X?\`4N_^3O\`]KH_X7A_U+O_`).__:Z/J&(_E_%?YA]>P_\`
M-^#_`,CUVBO(O^%X?]2[_P"3O_VNC_A>'_4N_P#D[_\`:Z/J&(_E_%?YA]>P
M_P#-^#_R/7:*\B_X7A_U+O\`Y.__`&NC_A>'_4N_^3O_`-KH^H8C^7\5_F'U
M[#_S?@_\CUVBO(O^%X?]2[_Y._\`VNC_`(7A_P!2[_Y._P#VNCZAB/Y?Q7^8
M?7L/_-^#_P`CUVBO(O\`A>'_`%+O_D[_`/:Z/^%X?]2[_P"3O_VNCZAB/Y?Q
M7^8?7L/_`#?@_P#(]=HKR+_A>'_4N_\`D[_]KH_X7A_U+O\`Y.__`&NCZAB/
MY?Q7^8?7L/\`S?@_\CUVBO(O^%X?]2[_`.3O_P!KH_X7A_U+O_D[_P#:Z/J&
M(_E_%?YA]>P_\WX/_(]=HKR+_A>'_4N_^3O_`-KH_P"%X?\`4N_^3O\`]KH^
MH8C^7\5_F'U[#_S?@_\`(]=HKR+_`(7A_P!2[_Y._P#VNC_A>'_4N_\`D[_]
MKH^H8C^7\5_F'U[#_P`WX/\`R/7:*\B_X7A_U+O_`).__:Z/^%X?]2[_`.3O
M_P!KH^H8C^7\5_F'U[#_`,WX/_(]=HKR+_A>'_4N_P#D[_\`:Z/^%X?]2[_Y
M._\`VNCZAB/Y?Q7^8?7L/_-^#_R/7:*\B_X7A_U+O_D[_P#:Z/\`A>'_`%+O
M_D[_`/:Z/J&(_E_%?YA]>P_\WX/_`"/7:*\B_P"%X?\`4N_^3O\`]KH_X7A_
MU+O_`).__:Z/J&(_E_%?YA]>P_\`-^#_`,CUVBO(O^%X?]2[_P"3O_VNC_A>
M'_4N_P#D[_\`:Z/J&(_E_%?YA]>P_P#-^#_R/7:*\B_X7A_U+O\`Y.__`&NC
M_A>'_4N_^3O_`-KH^H8C^7\5_F'U[#_S?@_\CUVBO(O^%X?]2[_Y._\`VNC_
M`(7A_P!2[_Y._P#VNCZAB/Y?Q7^8?7L/_-^#_P`CUVBO(O\`A>'_`%+O_D[_
M`/:Z/^%X?]2[_P"3O_VNCZAB/Y?Q7^8?7L/_`#?@_P#(]=HKR+_A>'_4N_\`
MD[_]KH_X7A_U+O\`Y.__`&NCZAB/Y?Q7^8?7L/\`S?@_\CUVBO(O^%X?]2[_
M`.3O_P!KH_X7A_U+O_D[_P#:Z/J&(_E_%?YA]>P_\WX/_(]=HKR+_A>'_4N_
M^3O_`-KH_P"%X?\`4N_^3O\`]KH^H8C^7\5_F'U[#_S?@_\`(]=HKR+_`(7A
M_P!2[_Y._P#VNC_A>'_4N_\`D[_]KH^H8C^7\5_F'U[#_P`WX/\`R/7:*\B_
MX7A_U+O_`).__:Z/^%X?]2[_`.3O_P!KH^H8C^7\5_F'U[#_`,WX/_(]=HKR
M+_A>'_4N_P#D[_\`:Z/^%X?]2[_Y._\`VNCZAB/Y?Q7^8?7L/_-^#_R/7:*\
MB_X7A_U+O_D[_P#:Z/\`A>'_`%+O_D[_`/:Z/J&(_E_%?YA]>P_\WX/_`"/7
M:*\B_P"%X?\`4N_^3O\`]KH_X7A_U+O_`).__:Z/J&(_E_%?YA]>P_\`-^#_
M`,CUVBO(O^%X?]2[_P"3O_VNC_A>'_4N_P#D[_\`:Z/J&(_E_%?YA]>P_P#-
M^#_R/7:*\B_X7A_U+O\`Y.__`&NC_A>'_4N_^3O_`-KH^H8C^7\5_F'U[#_S
M?@_\CUVBO(O^%X?]2[_Y._\`VNC_`(7A_P!2[_Y._P#VNCZAB/Y?Q7^8?7L/
M_-^#_P`CUVBO(O\`A>'_`%+O_D[_`/:Z/^%X?]2[_P"3O_VNCZAB/Y?Q7^8?
M7L/_`#?@_P#(]=HKR+_A>'_4N_\`D[_]KH_X7A_U+O\`Y.__`&NCZAB/Y?Q7
M^8?7L/\`S?@_\CUVBO(O^%X?]2[_`.3O_P!KH_X7A_U+O_D[_P#:Z/J&(_E_
M%?YA]>P_\WX/_(]=HKR+_A>'_4N_^3O_`-KH_P"%X?\`4N_^3O\`]KH^H8C^
M7\5_F'U[#_S?@_\`(]=HKR+_`(7A_P!2[_Y._P#VNC_A>'_4N_\`D[_]KH^H
M8C^7\5_F'U[#_P`WX/\`R/7:*\B_X7A_U+O_`).__:Z/^%X?]2[_`.3O_P!K
MH^H8C^7\5_F'U[#_`,WX/_(]=HKR+_A>'_4N_P#D[_\`:Z/^%X?]2[_Y._\`
MVNCZAB/Y?Q7^8?7L/_-^#_R/7:*\B_X7A_U+O_D[_P#:Z/\`A>'_`%+O_D[_
M`/:Z/J&(_E_%?YA]>P_\WX/_`"/7:*\B_P"%X?\`4N_^3O\`]KH_X7A_U+O_
M`).__:Z/J&(_E_%?YA]>P_\`-^#_`,CUVBO(O^%X?]2[_P"3O_VNC_A>'_4N
M_P#D[_\`:Z/J&(_E_%?YA]>P_P#-^#_R/7:*\B_X7A_U+O\`Y.__`&NC_A>'
M_4N_^3O_`-KH^H8C^7\5_F'U[#_S?@_\CUVBO(O^%X?]2[_Y._\`VNC_`(7A
M_P!2[_Y._P#VNCZAB/Y?Q7^8?7L/_-^#_P`CUVBO(O\`A>'_`%+O_D[_`/:Z
M/^%X?]2[_P"3O_VNCZAB/Y?Q7^8?7L/_`#?@_P#(]=HKR+_A>'_4N_\`D[_]
MKH_X7A_U+O\`Y.__`&NCZAB/Y?Q7^8?7L/\`S?@_\CUVBO(O^%X?]2[_`.3O
M_P!KH_X7A_U+O_D[_P#:Z/J&(_E_%?YA]>P_\WX/_(]=HKR+_A>'_4N_^3O_
M`-KH_P"%X?\`4N_^3O\`]KH^H8C^7\5_F'U[#_S?@_\`(]=HKR+_`(7A_P!2
M[_Y._P#VNC_A>'_4N_\`D[_]KH^H8C^7\5_F'U[#_P`WX/\`R/7:*\B_X7A_
MU+O_`).__:Z/^%X?]2[_`.3O_P!KH^H8C^7\5_F'U[#_`,WX/_(]=HKR+_A>
M'_4N_P#D[_\`:Z/^%X?]2[_Y._\`VNCZAB/Y?Q7^8?7L/_-^#_R/7:*\B_X7
MA_U+O_D[_P#:Z/\`A>'_`%+O_D[_`/:Z/J&(_E_%?YA]>P_\WX/_`"/7:*\B
M_P"%X?\`4N_^3O\`]KH_X7A_U+O_`).__:Z/J&(_E_%?YA]>P_\`-^#_`,CU
MVBO(O^%X?]2[_P"3O_VNC_A>'_4N_P#D[_\`:Z/J&(_E_%?YA]>P_P#-^#_R
M/7:*\B_X7A_U+O\`Y.__`&NC_A>'_4N_^3O_`-KH^H8C^7\5_F'U[#_S?@_\
MCUVBO(O^%X?]2[_Y._\`VNC_`(7A_P!2[_Y._P#VNCZAB/Y?Q7^8?7L/_-^#
M_P`CUVBO(O\`A>'_`%+O_D[_`/:Z],T#5?[<T*SU/R?(^TQ[_+W;MOMG`S^5
M95<-5I*\U8UI8BG5=H.YHT445@;!1110`4444`%%%%`!1110`4444`%%%%`!
M1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%
M%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`444
M4`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110
M`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!
M1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`>?
M?$3QUJGA*_LH+""SD2>(NQG1B00<<885QG_"Z/$?_/EI7_?J3_XNK?QL_P"0
MSI?_`%[M_P"A54^%?A?1O$G]K?VM9_:/L_D^5^]=-N[?G[I&?NCK7LTJ=".&
M56<;_P##GCU:E:6)=*$K?\,7;'XV7ZNHU#2;:5,_,;=V0X]@=W^?2O4/#WB7
M3/$]A]KTV8N%P)(W&'C)'1A_49'H:\U^('PTL=,TB35]"CDB6#!GMBY==G=E
M)R<COD]/3'/%>!_$4OAOQ/;7`<"VE80W(8X7RR>3]1U_"IEAJ->DYT59HJ.(
MK4*BA6=T?2U%%%>0>L>3^+OB-XG\+^([C3FLM,:$'S+=VBD)>,_=)^<<]0>.
MH-=#\/?'3^+8KJ"^2WAOX#O"0@@/&>,@$D\'@_45%\4_#*ZUX<:_@CS>Z>#(
M".K1_P`:_P!?P/K7B_AK7)?#OB"TU.+)$3_O$'\:'AE_+./?!KUZ5"EB,/[J
MM)?G_P`$\JI6J4,1[SO%_P!?@?0_B_Q$GA?PY<:B0C3#$=O&_1Y#T!]AR3[`
MUP_@[XA>)_%7B&&P%IIB6Z_O+B18I,K&#SCY^IS@?6N6^*'BN+Q#K4-K8SB7
M3[1/E=3Q([`%F_`8'X'UKT?X8>&/[!\-K=3KB]OPLK@CE$_@7\CD^YQVK)T8
M4<-S37O/8T56=;$<L'[J.WHHHKS3T3Q*]^,/B&VO[B!+/3"L4K("8I,X!(_O
MUWO@#QH?%VFS&Z6&+4('Q)'%D`H>C`$D^H//;WKP#5?^0Q??]?$G_H1K1\)>
M(9?#/B*VU!"?*SY<Z#^.,D;A^@(]P*]ZM@J<J7N*S/"I8RI&K[[NCW+X@^)[
MWPIH,%_816\DLETL)$ZL5VE7/8CGY14'P[\6W_BVPO9[^&VC:"5440*P!!&>
M<L:R?C#/%<^!]/G@D62*6]C='4Y#*8Y""/;%5_@G_P`@?5?^OA/_`$&N!4H?
M5'.VMSN=67UM0OI8]1HHHK@.\1W6-&=V"HHRS$X`'K7A\_QHUW[1)Y%CIPAW
M'RQ)&Y;;GC.'QG%>B_$G5_['\$7K(Q66ZQ:QD>K_`'O_`!T-7SO':3S6L]S'
M&3#!M$CY'R[C@?G@UZN7X>$XN=17/+Q^(G"2A!GT#\._&5SXNL+U[Z*WCN;:
M51M@4A=C#C@D\Y#5V=?/WPGU4Z?XUBMF($5[&T+9[$#<I^N5Q^-?0-<N-HJE
M5:CLSIP=5U:5WN@KF_'.MZCX=\-2:IIL5O(\,B"43J2-C';Q@@YW%?UKI*HZ
MSIR:OHM[I[XQ<PM'DG&"1P?P.#7/3:4TY;'143<&H[GEGA[XN:MJ'B&PLM0M
M-/2UN)EB=HD=6!;@')8CJ1VZ5[#7R21+;7!!W1RQ-C@X*L#_`#S7U/HNHKJ^
MAV.HJ`/M,"2$#H"1R/P.17?F&'A3Y905DSAP%>53FC-W9P?C[XD7_AG7TTW3
M8+.4+"KS-.KL58DX'##M@]^M=7X+UC4=?\,P:GJ4,,4L[,46%64;`<`X))YP
M3],5\_Z_>R>(_%]Y<1?.UW=;(1DG*YVH/RQ7TMIEC'IFEVEA$<I;0I$IQC(4
M`9_2EBZ4*5&$;>\QX6K.K5E*_NHM4445YQZ!P_Q$\;W7A&.P2PBMY;FY+EA.
M"P5%QV#`Y)/'T-<59?&76WO[9+NTTU;9I5$S)&X8)D;L$N><9K#^)VK_`-K>
M-[M58F*SQ:H/0K][_P`>+?I7*7=I/8W3VUS&8YH^&0D''&>U>]A\'2]DN=:L
M\/$8NI[5\CT1]:45S?@+53K'@K3;ER#*D?DR?5#MR?<@`_C725X<XN$G%]#V
MH24XJ2ZA7GWQ`\8^(?"-[;O:6EC+I]PN%DEC<LKCJI(8#IR/Q]*]!K(\3Z#!
MXDT"YTV;`9US$Y_@D'W6_/K[9K2A*$:B<U=$5HRE!J#LSAO!'Q0O-?\`$"Z9
MJT%G")D/D/`K+EQS@[F/49_'`[UU_C3Q.GA7P_+>@1O=,0EO$_1W/J!S@#D_
M_7KYQD2\T;5F0[H+RSFZCJCJ>H_$5L^,/%]UXNO+6:=!%';PA%C'3>0-[?B?
MT`KU9X",JL91^'K_`%YGE0QTHTI1E\73^O(]`\'_`!#\3^*?$,%@++35MQ^\
MN)%B?*1CKC+]3P!UY/I7JU<=\./"O_"-^'5>XCVZA>8EFW+AD&/E3\/YDUV-
M>9BI4W4:IJR1Z6&C-4TZCNV%%%%<YT!1110!D^)M4GT7PU?ZE;+&TUO%O19`
M2I.>^"#^M>0_\+H\1_\`/EI7_?J3_P"+KVG4].M]7TVXT^Z#&"==CA3@X^M<
M!KWPO\-:?X>U.]@BN1-;VDLL9,Q(W*A(X^HKNPDZ"7+55VV<6*A7;YJ;LK'*
M_P#"Z/$?_/EI7_?J3_XNC_A='B/_`)\M*_[]2?\`Q=<#80I<:C;0R9V22JC8
M]"0*]X_X5'X5_P">5U_W_-=]>.%H64X[G#0EBJU^66QW5%%%>$>V>7^.?B/K
M'AGQ*^FV5M8R0K$CAID<MDCV8#]*YO\`X71XC_Y\M*_[]2?_`!=4_BY_R/<O
M_7O'_*MWX8^#=`\0^&[B[U6P^T3I>-$K>=(F%"(<85@.I->TJ>'IX>-2<;['
MC.=>I7E3A*VYG?\`"Z/$?_/EI7_?J3_XNO0?AWXMO_%MA>SW\-M&T$JHH@5@
M"",\Y8U+_P`*P\'?]`?_`,F9O_BZVM$\.:3X<AEATJU^SI*P9QYC/DCC^(FN
M2O6PTH-4XV?]>9UT*6(C-.I*Z_KR-2BBL'QGK3:!X2O]0C8"=4V0^N]B%!'K
MC.?PKBA%RDHKJ=DI*,7)]#G_`!A\3['P[<R:?8PB]OTX?YL1Q'T)')(]!^>:
MX"7XO^*))"RFRB!_@2#@?F2?UKB((9[^^CACW2W%Q($7/)9F.!^))KZ!L?AA
MX9M](2SN;`7,VT>9<,[!V;N001@>P_7G/L3IX;"Q2FKMGDPJ8C%2;@[)'.^&
MOC"EY>1VNNVL-L)#M%U"2$4]MRG)`]\UZH"&4,I!!Y!'>OESQ-HQ\/\`B2^T
MO<66"3",V,E"`RDX[X(KW/X8ZN^K>"+7S6+RVC-;,Q[[<%?_`!UE%88W#0C!
M5:>S-L'B9RFZ53='8UD^)M4GT7PU?ZE;+&TUO%O19`2I.>^"#^M:U<YX]_Y$
M36/^O<_S%<%))SBGW1WU6U!M=CSS1/BWKVI:]IUA-:::L5S=10N4CD#!68`X
MR_7FO9J^7/"G_(XZ)_V$(/\`T8M?4==F84H4Y14%8X\!5G4BW-W/&=;^+>O:
M;KVHV$-IIK16UU+"A>.0L55B!G#]>*]0\,ZI/K7AJPU*Y6-9KB+>ZQ@A0<]L
MDG]:^<O%?_(XZW_V$)__`$8U?0'@+_D1-'_Z]Q_,UIC:-.%&,HJS_P"`9X.M
M.=649.Z_X)T=9/B;5)]%\-7^I6RQM-;Q;T60$J3GO@@_K6M7.>/?^1$UC_KW
M/\Q7GTDG.*?='H56U!M=CR[_`(71XC_Y\M*_[]2?_%U[#X?UJ#Q!H=KJ5N1B
M9`74'.Q_XE/T-?+%>C?"3Q/_`&9K3:-<RA;2^.8]QX6;@#_OH#'UVUZ^,P</
M9\U-6:/(PF,G[3EJ.Z9U?Q!^(.K>%->@L+"WLI(I+59B9T<MN+..S#CY179^
M&=4GUKPU8:E<K&LUQ%O=8P0H.>V23^M>0_&C_D<;3_L'I_Z,DKU'P%_R(FC_
M`/7N/YFN.O2A'#0FEJSLHU)RQ,XMZ(Z.BBL+QEK1T#PGJ&H(<3+'LAY&=[':
MI]\$Y^@-<48N4E%=3LE)1BY/H<YXR^)]KX=NFT_3X$O;Y.)"6Q'$?0XY)]AC
M'KVK@S\7_%!G\P?8@N<^6(#M^G7./QKC=/L[C6-6M[.(E[BZF"!FR>6/4_S)
MKWQ/A=X572Q9-8LSX&;GS&\PMC[V<X'TQCVKV)PPV%2C-7;/)A/$XEN4'9(R
M?!_Q6@UN\CT_5X(K.ZDXCE1CY3MV7!Y4GMR<UZ17RKK6FRZ'KMYISD[[:8H&
MZ$@'Y6_$8/XU]$>!M:?7O!]A>3.7N`IBF8]2ZG&3[D`'\:YL;AH02J4]F=&"
MQ,YMTZFZ.BK)\3:I/HOAJ_U*V6-IK>+>BR`E2<]\$']:UJYSQ[_R(FL?]>Y_
MF*XJ23G%/NCMJMJ#:['GFB?%O7M2U[3K":TTU8KFZBA<I'(&"LP!QE^O->S5
M\N>%/^1QT3_L(0?^C%KZCKLS"E"G**@K''@*LZD6YNX4445YYWA7G_C+XGVO
MAVZ;3]/@2]ODXD);$<1]#CDGV&,>O:NC\9:T=`\)ZAJ"'$RQ[(>1G>QVJ??!
M.?H#7S=I]G<:QJUO9Q$O<74P0,V3RQZG^9->C@<+&HG4J;(\_&XF5.T(;L[(
M_%_Q09_,'V(+G/EB`[?IUSC\:[3P?\5H-;O(]/U>"*SNI.(Y48^4[=EP>5)[
M<G-:R?"[PJNEBR:Q9GP,W/F-YA;'WLYP/IC'M7@^M:;+H>NWFG.3OMIB@;H2
M`?E;\1@_C733AA<2G&$;-'/.6)PS4IRNF?55%<[X&UI]>\'V%Y,Y>X"F*9CU
M+J<9/N0`?QKHJ\><7"3B^AZT)*<5)=0KS_QE\3[7P[=-I^GP)>WR<2$MB.(^
MAQR3[#&/7M71>,]:;0/"5_J$;`3JFR'UWL0H(]<9S^%?.&E:?-K.LVEA$V);
MJ98][<XR>6/TZUWX+"QJ)U*FR.'&XF5-JG3W9V)^+_B@S^8/L07.?+$!V_3K
MG'XUVOA#XK6^MWL>GZM!'9W4G$<J-^[=O3GE2>W)]*UH_AAX572ULGL"[A<&
MY,C"0MC[V<XSWQC'M7B.K^&-0T[7[S2X+:XNC!-Y2O'"QWYP5X`ZD$''O71"
M.%Q*<8JS1SSEBL.U*3NF?3]%8WA2ZOKSPMI\VI0S0WOE;9EG0H^Y25R0>><9
M_&MFO(E'E;78]>,N9)E#6[V33=!U&_A5&EMK669`X)4LJDC..W%>0V7QA\0W
M-_;P/9Z8%EE5"1%)G!(']^O5O%?_`")VM_\`8/G_`/1;5\SZ5_R&+'_KXC_]
M"%>E@*-.I"3DKGFXZM.$XJ+L?5]%%%>6>F<9\1/%M_X2L+*>PAMI&GE9&$ZL
M0`!GC#"O/O\`A='B/_GRTK_OU)_\771_&S_D#Z5_U\/_`.@UQ7PQT'3?$/B2
MXM-5MOM$"6;2JN]DPP=!G*D'H37L8:E16&]I.-SR<14K/$>SA*QI?\+H\1_\
M^6E?]^I/_BZZ3P-\1]8\3>)4TV]MK&.%HG<M"CAL@>[$?I71?\*P\'?]`?\`
M\F9O_BZO:1X(\.Z%?B]TW3_(N`I4/YTC<'KPS$5A4KX1P:C"S_KS-J='%*:<
MIZ?UY'0445!>3FVL;BX4!C%&S@'O@9KSDKGH/0X7QI\3[;P[<OIVFPI>7Z<2
M,S?NX3Z''+'U`(QZYXK@C\7O%)E+AK,*3G8(.![=<X_&N&EEDGF>:5R\DC%G
M8]23R37O6B>&_AYJNGPPZ?#979:/!W3'S^0>6&0P/![#VKVYTJ&%@N:/-YGC
M0JU\3-\LK>1F>%_B]#J-W'9:W:QVLDK!4N(2?+R3C#`\J/?)_#K7J%>-M\%K
MF36;@+J,4&F!_P!RQ!>4KC/(X'MG/;.*];TZS_L_3+6R,SS?9XEB\R3[S[1C
M)]^*X,6J%TZ+^1W85U[-55\RS1117&=84444`%%%%`!1110!XM\;/^0SI?\`
MU[M_Z%5SX'_\Q[_MW_\`:E4_C9_R&=+_`.O=O_0J/@[JVG:9_;7]H:A:VGF>
M1L^T3+'NQYF<9(SC(_.O9:;P%E_6IXZ:6.N_ZT/6M<$3>']2$^WRC:RA]QP-
MNPYS[8KY4KV;XB_$33I=$FTC1;H7,UT-DTT6=J1]QGN3TX[$^U>:^$=#D\0^
M)K.P5<QEP\QQP(UY;_#ZD5>`@Z-*4YZ$XZ:JU8PAJ?2]F9FL;<W&?/,:F3(Q
M\V.?UJ>BBO#9[2"OF_X@^&O^$:\3S11*!9W.9[<#^%2>5_`Y'TQ7TA7BWQL_
MY#.E_P#7NW_H5=^73:K<JV9P9A!.CS/='.?#KPT/$?BB)9XP]E:_OIP1D-C[
MJGZGMZ`U]&5Y%\#_`/F/?]N__M2O7:68S<JSB]D/+X*-%274****X3N/ES_F
M</\`M_\`_:E;/Q'\+_\`"-^)':",+87F9;<*,!>?F3\"?R(K&_YG#_M__P#:
ME?07C7PVOBCPW/9+@7*?O;9CVD`X'T/(_'/:O?KU_8U(-[-:GA4:'MJ<TMUL
M>%3^)FO/A_%H%RY:6TOEEMR1_P`LBD@(S[,1_P!]>U>B_!/_`)`^J_\`7PG_
M`*#7C$D;PRO%*C)(A*LK#!4CJ".QKV?X)_\`('U7_KX3_P!!HQL%'#RMU88*
M3E7C?HCU&BBD)"J68@`<DGM7@'NGB_QIU7SM6T_2D;Y;>(S.!_>8X'Y!?_'O
MRN^!O"HO_A;K&4)GU/=Y78'R_P#5_P#CX-><>)-3?Q!XIOK]`7^T3D1``Y*C
MY4&/7`%'_"*>(_\`H`:K_P"`<G^%?0*ART(T^;E>C_7\SP/;7K2J<MUM^GY&
M?9W4MC?6]Y`0)8)%E0GLRG(_45]66-W'?V%M>1?ZN>)94^C`$?SKY3N[*[T^
M<P7MK-;3``F.:,HV#WP>:]W^$NK'4/!JVKG,EC*T/3JI^93^I'X5CF=/FIJH
MNAMEL^6;@^IWE%%%>*>R?./Q)TK^RO'-^`"([HBZ3.>=_+=?]K=76^%_%/V3
MX/ZLC2`3V1:WBR0?];]W'K@LW'/W?2K?QJTDR66G:O&G,3M;RD#/#<KGT`(;
M_OJO(4NIDM);57(AE=7=0>"5#`?^A&O?I16)P\;]+?@>#5D\/7E;K?\`$ZWX
M7:2-4\;VKNFZ*S4W+<<9'"_^/$'\*^AZ\P^"^E>1HU_JC@;KF41)TX5!S],E
MO_'17I]>;F%3GK-=M#T<!3Y**??4*HZSJ*:1HM[J#XQ;0M)@C.2!P/Q.!5ZO
M-_C)J_V3PW;Z8C#S+V7+#_IFF"?_`![;^1KGH4_:5%#N=%>I[.FY=CR?PSIS
M>(/%UA9S$N+BX#3'N5'S/^@-=9\8]*^R>*8-05<)>P#<?5T^4_\`CNRN&L='
MU34T=[#3;R[5#AF@@:0*?0X'%37'AS7+2!Y[G1M1AA09>22U=54>I)&!7T,H
MKVJES;:6/`C)^R<>7?6YZ3\%-5.[4](8C&!=1C\E;_V2O7J^9O`VK'1?&6FW
M1.(VE$,G&?E?Y2?PSG\*^F:\C,:?+6YNYZV7U.:ER]@HHKG/&_B5?"_AR:\1
MD^UO^[MD;NY[X]`.?_UUQ0@YR48[L[)S4(N3V1Y!\5[K3[KQM-]B0^;%&L=T
MX/#R#T]P,`_3';GG?"]U867B?3KG5(C)9QS!I%]/0GU`."1W`Q5OP?X?F\5^
M)X+1][0[O.NY">0@///J>GU.:B\7>'I?#'B.XTY\F+_60/\`WXST/U'(/N#7
MTD.2*^KWUL?/3YY/V]M+GTZ"&4,I!!Y!'>EKSOX3>*/[5T0Z/<R`W=@H$>3R
M\/0?]\_=^FVO1*^=K4G2FX/H>_2J*I!374****S-`HHHH`*R/%?_`")VM_\`
M8/G_`/1;5KUD>*_^1.UO_L'S_P#HMJNG\:]2*GP,^9]*_P"0Q8_]?$?_`*$*
M^KZ^4-*_Y#%C_P!?$?\`Z$*^KZ]/-=X_,\[+-I?(****\D]0^?\`XN?\CW+_
M`->\?\JY.R_M7R3]A^V^5NY\C=MW?AWZ5UGQ<_Y'N7_KWC_E72?"OQ-HNB^&
M+FVU+48;:9KUI`DA.2I1!G\P?RKZ"-1T\-&2C?1'@RIJIB91;MJSSC_BHO\`
MJ*?^1*^HZYS_`(3WPK_T'+7\S_A6II>MZ;K<4DFFWD=RD9VN8ST->9BZLZJ3
M<+6/1PM*%)M*=[E^O/\`XQ-*/!*",95KR,2<=%VM_7;7H%<WX]T=];\&:A:Q
M#,Z()HAR<LAW8`'<@$?C6&'DHU8M]S?$1<J4DNQX1X(CCD\;Z,LH&T72,,G'
M(.1^H%?3=?)VG7KZ;JEI?1J&>VF290>Y5@1_*OI*S\:^'+W3!?IJ]K'$%#.L
MLJJZ$]BI.<]?KCC->AF=.3E&26AP9;4BHRBV:;Z3ITES)<OI]JT\N/,E:%2S
MX&!DXR<#BK$%O!;(4@ACB0G)6-0HSZ\5\]^+/'FI:IXCN;C2=4O[6P!"0I%<
M/&&`&-Q`/4G)_*O6OALVJ2^#H+G5;F>XFN':2-IV+,(^`O)YQP3SZURUL+.E
M34Y/?H=-'%0J5'"*^9UU<YX]_P"1$UC_`*]S_,5T=<YX]_Y$36/^O<_S%<]'
M^)'U1T5OX<O1GS7%YGG)Y._S=PV;,[MW;&.]:G_%1?\`44_\B4>%/^1QT3_L
M(0?^C%KZCKW,7BO822Y;W/%PF%]M%OFM8^2)?,\Y_.W^;N._?G=N[YSWKZ4\
M!?\`(B:/_P!>X_F:^?\`Q7_R..M_]A"?_P!&-7T!X"_Y$31_^O<?S-8YB[T8
MO^MC;+E:M)?UN='7.>/?^1$UC_KW/\Q71USGCW_D1-8_Z]S_`#%>31_B1]4>
MI6_AR]&>+?#G3+?6?$LFG7:!H;BTE1N.G`P1[@X(]Q6!JVFW>@:W<6%P2ES:
MR8W*2,]U8>Q&"/K75_"/_D>XO^O>3^5=E\7O"YOM.CUZU0F>T&RX51RT6>&_
MX"3^1)[5[DJ_)B>1[-?B>+&ASX;G6Z?X'FWC#Q'_`,)/<Z9>N?\`28[!(;GY
M<#S%=\D?4$'CUQ7NG@+_`)$31_\`KW'\S7S17TOX"_Y$31_^O<?S-89C!0HQ
MBMKFV7S<ZLI/>QT=<+\7/^1$E_Z^(_YFNZKGO'.C2:[X/U"RA3?<;!)".Y93
MNP/<X(_&O,P\E&K%ON>G7BY4I)=CP[X=)$_C_2!,Y5?,8@C^\$8J/Q.!7TE7
MRGHNI/HVMV6HQC<;:99-O]X`\C\1D5]'1>-/#DNEKJ/]L6B0$`D/*`ZG&=I7
MKN]L5Z&9TY.<9)'!EU2*A*+9XC\3_P#DHNJ_]L?_`$4E>C_!@D^#KH$D@7[@
M>W[N.O'O$>K'7?$5_J9#!;B4L@;J$Z*#R>0`*]\^'.DOH_@FQBE4K-.#<.I[
M;N1_X[MZUIC/<PL8/?3\C/!^_B936VIU5<YX]_Y$36/^O<_S%='7.>/?^1$U
MC_KW/\Q7DT?XD?5'J5OX<O1GS_X4_P"1QT3_`+"$'_HQ:^HZ^6/#EQ%:>)])
MN9W$<,5[#)(YZ*H<$G\J^A/^$]\*_P#0<M?S/^%>GF4)2G'E5SSLNG&,9<SL
M='163I?B;1=:N6MM-U&&YF5#(4C)R%!`S^9'YUK5Y,HN+LU8]2,E)73.%^+G
M_(B2_P#7Q'_,UY1\.5B;X@:0)CA/,8CG^((Q7]<5[AXYT:37?!^H64*;[C8)
M(1W+*=V![G!'XU\Z:+J3Z-K=EJ,8W&VF63;_`'@#R/Q&17L8'W\/*"WU_%'D
M8WW,1&;VT_!GU97SG\3_`/DHNJ_]L?\`T4E>W1>-/#DNEKJ/]L6B0$`D/*`Z
MG&=I7KN]L5\[^(]6.N^(K_4R&"W$I9`W4)T4'D\@`5GEM.<:DI-=+&F8U(NF
MDGU/8?@P2?!UT"20+]P/;]W'7HM<K\.=)?1_!-C%*I6:<&X=3VW<C_QW;UKJ
MJX<3)2K2:[G=AHN-**?8\]^,DDB>"X50G:]ZBOQGC:Y_F!7FOPQ`;XB:4"`1
M^]//_7)Z]C^(NE2:OX(OXH0S2P@3HJ_Q;#DCWXS^.*^?]`U:30M>LM3C!8V\
MH9E!P67HRY]P2/QKT\%[^%E!;Z_D>;C/<Q,9O;0]H^(GCK5/"5_906$%G(D\
M1=C.C$@@XXPPKC/^%T>(_P#GRTK_`+]2?_%UW^J/X"\5VD.J:G=V<\<285GN
MVB9`><%0P.?8C->%:Y)ITNMW;:3#Y.G^81`F6/RC@'YB3SC//K2P=*E./+*&
MJW;#%U:L)<T9Z/:Q]&^#=:N?$/A2RU6[2))Y]^Y8@0HVNRC`))Z`=ZW:Y'X8
M?\DZTK_MM_Z->NNKRZZ4:LDN[/4HMRIQ;[(R/%?_`")VM_\`8/G_`/1;5\SZ
M5_R&+'_KXC_]"%?3'BO_`)$[6_\`L'S_`/HMJ^9]*_Y#%C_U\1_^A"O4RW^'
M,\S,?XD3ZOHHHKQCUSR[XV?\@?2O^OA__0:\?LOMOG'[#]H\W;SY&=VW\.W2
MO8/C9_R!]*_Z^'_]!KC_`(5ZOI^B^)[FYU*ZCMH6LFC#R="Q=#C\@?RKW<))
MPPG,E??\SP\5%2Q7*W;8YW_BHO\`J*?^1*]Z^'/VG_A`]-^U^;Y_[W=YN=W^
MM?&<\],5-_PGOA7_`*#EK^9_PJWIWBK0M7NQ:Z?J<%Q.06"(3G`ZUQ8FO4JP
MLX6MJ=N&HPI3NIWN;%%%9?B+5WT'0+O5$M&NC;J'\E6V[AD`G.#@`$GIVK@C
M%R:2.Z344VSQ+QA\-M4T.^EFTVVFO-,;+(T2[FB']U@.>/7I7#D%6((((X(/
M:O5;'XSWDNM6XO;&V@TPOB7RPS2*"",YS@X.#T[5Z'=7/A'6K(W%Y/H]U`1D
MR3/&=O'J>5(S[$5[?UJM12C6C?S1XWU:C6;=*5O)GAGA[QYKOAZXB,=Y+<6J
M\-:SN60KGD#/W3[BOH;1]5M];T>UU*T),-P@<`]5/0J?<$$'Z5\Q:VFGQZW>
MKI3L]@)6$#-G)7MUYQ]:][^%]K-:^`=/\XOF4R2*K#[JESC'L?O?\"K/,:<.
M15$K,TR^I/G=-NZ.PHHHKQSU@HHHH`****`"BBB@#S#XH^$M<\1ZE83:59?:
M(XH65SYJ)@DY_B(K@O\`A6'C'_H#_P#DS#_\77T917=2Q]2G!025E_7<XJN!
MIU)N;;U_KL>!V'PA\373+]J%K9(1EC)*'(Y]%SSWZUZWX4\'Z=X2LFBM-TEQ
M+CSKA_O28SCCH`,]!^M=#16=;&5:RM)Z&E'"4J3O%:A1117*=(5YA\4?"6N>
M(]2L)M*LOM$<4+*Y\U$P2<_Q$5Z?16M&K*E/GCN95J4:L.21YS\*_"^L^&_[
M6_M:S^S_`&CR?*_>H^[;OS]TG'WAUKT:BBE6JNK-SENQTJ2I04([(****S-#
MP7_A7/BO_A)/M?\`97[C[9YN[[1%]W?G.-V>E>]445T5\1*M;FZ&%##QHWY>
MIY#\0_AQJ6H^(/[2T&T$ZW0+7$?F(FR0=_F(X8?7D'U%=#\+O#FK>'--OX=5
MM?L[RS*R#S%?(`Q_"37>T54L74E2]D]OQ)CA81J^U6X5D^)TU"7PSJ$6E0>=
M>RPF.)-P7EOE)R2!P"3U[5K45S1?*TSHDKIH\1\&_#?Q!9^+-/O-5T\06EO)
MYS.9HV^91E0`K$_>Q7MU%%;5\1.O+FD94*$:,>6)YA\4/!.J>(-1L;_1[07$
MHB,4X\Q4(`.5/S$`]6_*H_ACX9\2^&=9NQJ6G>397,(#/YT;8=3\O"L3T+=N
M]>IT5?UN?LO8M*Q'U2'M?:INX4445RG28?B_13X@\*W^G(H:9X]T.<?ZQ>5Y
M/3)&,^A->'_\*P\8_P#0'_\`)F'_`.+KZ,HKJH8RI0BXQL<M?"4ZTN:5S(\+
MZ3_8?AC3M-90LD,($@!R/,/+X/IN)K7HHKFE)R;D^ITQBHI)=`KR/XD>%/%/
MB7Q,);'3/-LH(5CB?SXUW'[S'!8'J<=.U>N45K0K2HRYXK4SK456CRR>ARWP
M^\/W'AOPG#9WD8CNY)'FF0,&PQ.`,C@_*%KH-1LH]2TRZL9L>7<1-$V1GAAB
MK-%1.I*4W-[E1@HP4%L?.A^%_C$,0-(!`[BYBY_\>KW[1VO7T:S.I1>5>^2H
MG3<&P^.>02.OO5VBML1BIUTE)+0QH86%!MQ;U"O'_B!X:\8>*?$+26^E.=/M
MAY=L#<Q#(_B?!?C<?QP!FO8**BA6=&7-%*_F76HJM'ED]#C?ASX1?POH;->1
MA=2NCNG&X-L`)VJ"..G/U/M3/B1X1D\3Z+')8PJ^I6S9B&0I=3]Y<G`]^?3W
MKM:*/K$_:^UZA["'LO9=#P?P]X*\<^'M=M=3M](.Z%OG7[5#AT/#*?G[C_&O
M=T8LBL5*$C)4XR/;CBEHJJ^(E7:<DKBH8>-%-1;"BBBN<W"BBB@`K.\06LU]
MX;U6TMDWSSV<L4:Y`W,R$`9/`Y-:-%.+L[B:NK'SYI_PT\70:E:S2:3M1)D9
MC]IB.`""?XJ^@Z**WQ&)G7:<NAA0PT*%U'J%%%%<YT'C_P`1?!'B+7?%DE[I
MNG^?;F%%#^=&O('/#,#7)_\`"L/&/_0'_P#)F'_XNOHRBN^GF%6$5%):?UW.
M&>`I3DY-O7^NQ\Y_\*P\8_\`0'_\F8?_`(NO3_A=X<U;PYIM_#JMK]G>6960
M>8KY`&/X2:[VBHK8ZI5AR22L51P5.E/GBV%%%%<9V'EGC'X3G4;V74=!DBAD
ME.Z2UDX4MW*GMGTZ>_:N`?X=>+8YQ"=%F+'`!5T*\_[0./UKZ2HKNI9A5A'E
MW.*I@*4WS;'BWAKX/WTUPD_B!TM[=2";:)PSO[$C@#Z$GZ=:]GCC2&)(HD5(
MT`5548"@=`!V%.HK"OB)UG>9O1P\**M`*Q?%UA<ZIX3U*RLXO-N)H2L:;@N3
MD=S@5M45E&3C)270TE%2BXOJ>"^'_ASXKL?$FE7=SI6R""\BED;[1$=JJX).
M`V3P*]ZHHK;$8B5=IRZ&5##QH)J/4\%\0?#GQ7?>)-5N[;2M\$]Y++&WVB(;
ME9R0<%LC@U[!X1L+G2_">FV5Y%Y5Q#"%D3<&P<GN,BMJBG6Q4ZL%"26A-'"P
MI2<XMZA6+XNL+G5/">I65G%YMQ-"5C3<%R<CN<"MJBL(R<9*2Z&\HJ47%]3Q
M_P"'7@CQ%H7BR.]U+3_(MQ"ZE_.C;DCCA6)KUV6*.>%X94#QR*5=3T(/!%/H
MK2O7E6GSRW,Z-"-&/+'8\!UCX5>(H-8NH]+L#<V(<F"4SQJ2IY`(+`Y'0\=J
M]D\(V%SI?A/3;*\B\JXAA"R)N#8.3W&16U15UL74K149="*.%A1DY1ZA1117
M,=)Y3XU^%,E_>R:EX?,2/*=TMHYV@L>I0]!GT.!Z'M7!GX=>+1<>0=%FW],A
MT*_]]9Q^M?25%=U/,*L(\NYPU,!2G+FV/(_!_P`))8+J'4/$+Q_NR'6RC.[)
M[;V'''H,Y]>U>N445SUJ\ZTN:;.FC0A1C:`5B^+K"YU3PGJ5E9Q>;<30E8TW
M!<G([G`K:HK.,G&2DNA<HJ47%]3YS_X5AXQ_Z`__`),P_P#Q='_"L/&/_0'_
M`/)F'_XNOHRBN_\`M.MV7X_YG#_9M+N_P_R/*/ACX-U_P]XDN+O5;#[/`]FT
M2MYT;Y8NAQA6)Z`UZO117'6K2K3YY'71HQHQY8A7E/C7X4R7][)J7A\Q(\IW
M2VCG:"QZE#T&?0X'H>U>K444:TZ,N:`5J,*L>69\VGX=>+1<>0=%FW],AT*_
M]]9Q^M=MX/\`A)+!=0ZAXA>/]V0ZV49W9/;>PXX]!G/KVKURBNJIF-:<>5:'
M-3R^E"5WJ%%%%<!W!7D'B_X23RWLE[X<$7EO\S6;-MVM_L$\8]CC'TZ>OT5M
M1KSHRYH&-:A"M&TSYN7X<^+6G,(T67>.YD0+_P!];L?K713_``>U6#PXTZ2)
M<:L9%*VT3@($YR-S8!;D'TX/7->WT5U2S*L[6LCFCEU)7O=G.>`]+O-&\%Z?
MI^H0^3=1>9OCW!L9D9AR"1T(KHZ**X9R<Y.3ZG;"*A%170SO$%K-?>&]5M+9
M-\\]G+%&N0-S,A`&3P.37ANG_#3Q=!J5K-)I.U$F1F/VF(X`()_BKZ#HK>AB
MIT8N,4M3"MA85FI2;T"BBBN8Z3@OBCX<U;Q'IMA#I5K]H>*9F<>8J8!&/XB*
M\P_X5AXQ_P"@/_Y,P_\`Q=?1E%=E''5*4.2*5CCK8*G5GSR;/G/_`(5AXQ_Z
M`_\`Y,P__%UUGPZ\$>(M"\61WNI:?Y%N(74OYT;<D<<*Q->P45=3,*LXN+2U
M_KN3#`4H24DWI_78*9+%'/"\,J!XY%*NIZ$'@BGT5P'<>+>)?@_?0W#S^'W2
MXMV)(MI7"NGL">"/J0?KUKE?^%=^+?/\G^Q9]^<9WIM_[ZSC]:^DZ*]"&95H
MJSLS@GEU*3NKH\6\-?!Z_FN8Y_$$B6]NI!-M&^YY/8L.%'N"3].M>S111P0I
M#$@2.-0J*.@`X`I]%<U?$5*SO,Z:.'A15H!1116!L%%%%`!1110`4444`%%%
M%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444
M`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`
M4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1
M110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%
M%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444
M`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`
M4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1
M110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%
M%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444
M`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`
..4444`%%%%`!1110!_]D_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
